A bill to decriminalize and deschedule cannabis, to provide for reinvestment in certain persons adversely impacted by the War on Drugs, to provide for expungement of certain cannabis offenses, and for other purposes.

On July 16, 2026, Senator Cory Booker (D-NJ) introduced S5022, a bill to decriminalize and deschedule cannabis, provide reinvestment in communities impacted by the War on Drugs, and expunge certain cannabis offenses. The bill was read twice and referred to the Committee on Finance. This is an early-stage procedural action; the bill has not been marked up, passed, or signed into law. The bill has 16 cosponsors, all Democrats, including Senate Majority Leader Schumer and Finance Committee Chair Wyden. The bill's referral to the Finance Committee, rather than Judiciary, suggests a focus on tax and revenue implications of cannabis legalization rather than criminal justice reform.

The money trail: S5022 does not authorize or appropriate any specific funding amount. The bill's primary mechanism is regulatory: removing cannabis from the Controlled Substances Act (descheduling) and eliminating federal criminal penalties for cannabis-related activities. This would not directly allocate government funds but would enable state-legal cannabis businesses to access traditional banking, capital markets, and interstate commerce, potentially generating significant tax revenue. The Congressional Budget Office would need to score the bill's revenue impact if it advances.

Convergence: No related signals or procurement data were provided. This bill stands alone as a legislative proposal with no immediate market-moving catalysts.

Structural winners: US multi-state cannabis operators (MSOs) like Tilray Brands ($TLRY) and Canopy Growth ($CGC) would be primary beneficiaries if the bill advances, as federal descheduling removes the primary legal risk that has constrained their access to banking, capital, and interstate operations. The AdvisorShares Pure US Cannabis ETF provides diversified exposure to the sector. However, the bill is in early stage and faces significant legislative hurdles in a divided Congress.

Timeline: The bill is at the beginning of the legislative process. It must be marked up by the Finance Committee, pass the Senate, pass the House, and be signed by the President. Given the partisan nature of the cosponsors and the current political landscape, passage in the 119th Congress is highly uncertain.